Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling

Birgit Wilding; Dirk Scharn; Dietrich Böse; Anke Baum; Valeria Santoro; Paolo Chetta; Renate Schnitzer; Dana A. Botesteanu; Christoph Reiser; Stefan Kornigg; Petr Knesl; Alexandra Hörmann; Anna Köferle; Maja Corcokovic; Simone Lieb; Guido Scholz; Jens Bruchhaus; Markus Spina; Josef Balla; Biljana Peric-Simov; Jasmin Zimmer; Sophie Mitzner; Thomas N. Fett; Alexandra Beran; Lyne Lamarre; Thomas Gerstberger; Daniel Gerlach; Markus Bauer; Andreas Bergner; Andreas Schlattl; Gerd Bader; Matthias Treu; Harald Engelhardt; Stephan K. Zahn; Julian E. Fuchs; Johannes Zuber; Peter Ettmayer; Mark Pearson; Mark Petronczki; Norbert Kraut; Darryl B. McConnell; Flavio Solca; Ralph A. Neumüller

doi:10.1038/s43018-022-00412-y

Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling

Birgit Wilding(Boehringer Ingelheim (Austria)), Dirk Scharn(Boehringer Ingelheim (Austria)), Dietrich Böse(Boehringer Ingelheim (Austria)), Anke Baum(Boehringer Ingelheim (Austria)), Valeria Santoro(Boehringer Ingelheim (Austria)), Paolo Chetta(Boehringer Ingelheim (Austria)), Renate Schnitzer(Boehringer Ingelheim (Austria)), Dana A. Botesteanu(Boehringer Ingelheim (Austria)), Christoph Reiser(Boehringer Ingelheim (Austria)), Stefan Kornigg(Boehringer Ingelheim (Austria)), Petr Knesl(Boehringer Ingelheim (Austria)), Alexandra Hörmann(Boehringer Ingelheim (Austria)), Anna Köferle(Boehringer Ingelheim (Austria)), Maja Corcokovic(Boehringer Ingelheim (Austria)), Simone Lieb(Boehringer Ingelheim (Austria)), Guido Scholz(Boehringer Ingelheim (Austria)), Jens Bruchhaus(Boehringer Ingelheim (Austria)), Markus Spina(Boehringer Ingelheim (Austria)), Josef Balla(Boehringer Ingelheim (Austria)), Biljana Peric-Simov(Boehringer Ingelheim (Austria)), Jasmin Zimmer(Boehringer Ingelheim (Austria)), Sophie Mitzner(Boehringer Ingelheim (Austria)), Thomas N. Fett(Boehringer Ingelheim (Austria)), Alexandra Beran(Boehringer Ingelheim (Austria)), Lyne Lamarre(Boehringer Ingelheim (Austria)), Thomas Gerstberger(Boehringer Ingelheim (Austria)), Daniel Gerlach(Boehringer Ingelheim (Austria)), Markus Bauer(Boehringer Ingelheim (Austria)), Andreas Bergner(Boehringer Ingelheim (Austria)), Andreas Schlattl(Boehringer Ingelheim (Austria)), Gerd Bader(Boehringer Ingelheim (Austria)), Matthias Treu(Boehringer Ingelheim (Austria)), Harald Engelhardt(Boehringer Ingelheim (Austria)), Stephan K. Zahn(Boehringer Ingelheim (Austria)), Julian E. Fuchs(Boehringer Ingelheim (Austria)), Johannes Zuber(Research Institute of Molecular Pathology), Peter Ettmayer(Boehringer Ingelheim (Austria)), Mark Pearson(Boehringer Ingelheim (Austria)), Mark Petronczki(Boehringer Ingelheim (Austria)), Norbert Kraut(Boehringer Ingelheim (Austria)), Darryl B. McConnell(Boehringer Ingelheim (Austria)), Flavio Solca(Boehringer Ingelheim (Austria)), Ralph A. Neumüller(Boehringer Ingelheim (Austria))

Nature Cancer

July 26, 2022

10.1038/s43018-022-00412-y

Cited by 49

Abstract

Related Papers

No related papers found

Powered by citation graph analysis